NDA 020941 · Haleon US Holdings
Abreva
Docosanol · Topical
NovelLast checked: Nov 20, 2026Latest source record: Apr 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Jul 25, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
1 Phase 3, 0 recruiting
FAERS reports
14,600
280 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 20, 2024.
Uses treats cold sores/fever blisters on the face or lips shortens healing time and duration of symptoms: tingling, pain, burning, and/or itching
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ABREVA · DOCOSANOL 10% · CREAM, TOPICAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Docosanol" as an intervention, any sponsor and status, largest first.
- An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes LabialisPivotal-lookingStatus unknown
Laboratoire Boreaderme Inc.Industry
NCT03977792 · 164 participants (planned) · Start Sep 2020 · Primary completion Jul 2021
Drug: BOR15001L7; Docosanol Cream 10% · For: Recurrent Herpes Labialis
Hadassah Medical OrganizationAcademic, hospital or other
NCT00467662 · 75 participants (planned)
Drug: Acyclovir 5%; Docosanol 10% · For: Reccurent Herpes Labialis
University of UtahAcademic, hospital or other
NCT06558838 · 58 participants · Start Aug 19, 2024 · Primary completion Nov 30, 2025
Drug: acyclovir-penciclovir cream; Abreva · For: Herpes Simplex Oral
Sites: Murray, Utah
- Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin TreatmentPivotal-lookingCompleted
Universitas IndonesiaAcademic, hospital or other
NCT06178367 · 36 participants · Start Aug 26, 2023 · Primary completion Sep 30, 2023
Drug: Low molecular weight hyaluronic acid; High molecular weight hyaluronic acid and 1 more · For: Xerosis Cutis
Sites: Jakarta, Indonesia
University of UtahAcademic, hospital or other
NCT04893577 · 10 participants · Start Jan 20, 2022 · Primary completion Aug 31, 2024
Drug: EDTA; Abreva · For: Herpes Simplex Oral
Sites: Murray, Utah
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective7,071
- oral herpes2,458
- condition aggravated1,967
- drug administration error1,779
- incorrect drug administration duration803
- herpes simplex706
- incorrect product administration duration642
- lip swelling560
- wrong technique in product usage process552
- product quality issue539
- inappropriate schedule of drug administration493
- application site pain448
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 1,157 |
| 2006 | 1,355 |
| 2007 | 1,648 |
| 2008 | 5 |
| 2009 | 14 |
| 2010 | 9 |
| 2011 | 17 |
| 2012 | 13 |
| 2013 | 2,116 |
| 2014 | 216 |
| 2015 | 1,337 |
| 2016 | 974 |
| 2017 | 1,006 |
| 2018 | 1,074 |
| 2019 | 855 |
| 2020 | 479 |
| 2021 | 453 |
| 2022 | 333 |
| 2023 | 852 |
| 2024 | 344 |
| 2025 | 219 |
| 2026 | 119 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical and Systemic Therapeutic Approaches in the Treatment of Oral Herpes Simplex Virus Infection: A Systematic Review.
Mancini A, Inchingolo AM, Marinelli G, et al. · Int J Mol Sci 2025 · Systematic Review
- n-Docosanol 10% cream in the treatment of recurrent herpes labialis: a randomised, double-blind, placebo-controlled study.
Habbema L, De Boulle K, Roders GA, et al. · Acta Derm Venereol 1996 · Clinical Trial, Randomized Controlled Trial
- Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial.
Sacks SL, Thisted RA, Jones TM, et al. · J Am Acad Dermatol 2001 · Clinical Trial, Multicenter Study
- The antiviral drug docosanol as a treatment for Kaposi's sarcoma lesions in HIV type 1-infected patients: a pilot clinical study.
Scolaro MJ, Gunnill LB, Pope LE, et al. · AIDS Res Hum Retroviruses 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Haleon US Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.